{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39(5)"],"submitter":["Menzies-Gow A"],"funding":["AstraZeneca Schweiz"],"pubmed_abstract":["<h4>Introduction</h4>Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months.<h4>Methods</h4>In previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β<sub>2</sub>-agonists. This post hoc analysis included patients randomized to the approved benralizumab dose and not receiving oral corticosteroid"],"journal":["Advances in therapy"],"pagination":["2065-2084"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9056458"],"repository":["biostudies-literature"],"pubmed_title":["Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab."],"pmcid":["PMC9056458"],"pubmed_authors":["Hoyte FL","Barker P","Kreindler J","Brooks CL","Jison M","Katial R","Price DB","Menzies-Gow A","Cohen D","Papeleu P"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.","description":"<h4>Introduction</h4>Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months.<h4>Methods</h4>In previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β<sub>2</sub>-agonists. This post hoc analysis included patients randomized to the approved benralizumab dose and not receiving oral corticosteroid","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-31T14:03:56.318Z","creation":"2024-11-19T21:20:37.56Z"},"accession":"S-EPMC9056458","cross_references":{"pubmed":["35287231"],"doi":["10.1007/s12325-022-02098-1"]}}